等待開盤 11-19 09:30:00 美东时间
-0.044
-9.11%
Coherus BioSciences (NASDAQ:CHRS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
11-10 07:07
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Companies Reporting Before The Bell • ZIM Integrated Shipping (NYSE:ZIM) is exp...
03-09 19:11
Coherus BioSciences (NASDAQ:CHRS) is set to give its latest quarterly earnings ...
03-07 00:00
In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the Offering, at the public offering price per
02-13 05:26
Coherus Oncology, Inc. (NASDAQ:CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus chemotherapy in
2025-12-08 21:48
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Coherus BioSciences (NASDAQ:CHRS) is gearing up to announce its quarterly earni...
2025-11-06 04:03
Coherus Oncology changes its name to emphasize its focus on innovative immuno-oncology therapies. The company highlights its pipeline of combination therapies targeting immune resistance, including LOQTORZI, CHS-114, and Casdozokitug, aiming to improve cancer treatment outcomes.
2025-05-30 12:00
Coherus BioSciences and STORM Therapeutics are collaborating on a Phase 1b/2 study evaluating the combination of STC-15, a METTL3 inhibitor, and LOQTORZI, a PD-1 inhibitor, for treating non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and endometrial cancer. The trial aims to assess safety and efficacy, with up to 188 patients enrolled in the U.S.
2025-05-27 12:30